Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 2/20 | 0.51 |
| ▸ | ESR1 | P03372 | 3/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 2/20 | 0.40 |
| ▸ | PLK1 | P53350 | 2/20 | 0.40 |
| ▸ | PKN1 | Q16512 | 2/20 | 0.40 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.40 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | NEK2 | P51955 | 1/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1095047 | 0.86 | HSD17B3 (0.44) | HSD17B3ESR1ESR2PTGS1PTGS2 | |
| SCHEMBL21379597 | 0.82 | HSD17B3 (0.46) | HSD17B3ESR1ESR2CLK2KDM4E | |
| SCHEMBL3063473 | 0.79 | HSD17B3 (0.44) | HSD17B3ESR1ESR2SRCCLK2 | |
| SCHEMBL20957619 | 0.78 | HSD17B3 (0.58) | HSD17B3ESR1ESR2NUAK1IGF1R | |
| SCHEMBL2454830 | 0.78 | ALDH1A1 (0.50) | HSD17B3PTGS1PTGS2KDM4EALDH1A1 | |
| SCHEMBL25190307 | 0.77 | HSD17B3 (0.42) | HSD17B3ESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL10790857 | 0.76 | HSD17B3 (0.51) | HSD17B3ESR1ESR2KDM4EALDH1A1 | |
| SCHEMBL4058366 | 0.76 | RXFP1 (0.47) | HSD17B3KDM4EALDH1A1CASP1CASP7 | |
| SCHEMBL8570027 | 0.74 | CA12 (0.43) | ALDH1A1GAASMN1; SMN2LMNAMAOA | |
| SCHEMBL27907872 | 0.72 | ALDH2 (0.47) | HSD17B3ESR1ESR2PTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106249503-A | Optical element and electrophoretic display for display device | 广州奥翼电子科技股份有限公司 | 2016-12-21 | — | — | CN | claimed |
| EP-2287607-B1 | METHOD FOR QUANTIFICATION OF ANTIGEN-SPECIFIC CANINE OR HUMAN IGE | RIKEN (JP) | 2018-08-22 | — | — | EP | disclosed |
| US-8716031-B2 | Method for quantification of antigen-specific canine IgE | RIKEN (JP) | 2014-05-06 | — | — | US | disclosed |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-11-10 | — | — | US | disclosed |
| US-7947682-B2 | Substituted N′-pyrrolo[1,2-a]quinoxalin-4-yl-hydrazides as anti-cancer agents | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110111529-A1 | METHOD FOR QUANTIFICATION OF ANTIGEN-SPECIFIC CANINE OR HUMAN IGE | RIKEN (JP) | 2011-05-12 | — | — | US | disclosed |
| EP-2287607-A1 | METHOD FOR QUANTIFICATION OF ANTIGEN-SPECIFIC CANINE OR HUMAN IGE | Riken (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-02-10 | — | — | US | disclosed |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2010-05-13 | — | — | US | disclosed |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-04-09 | — | — | US | disclosed |
| EP-1816913-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-10-19 | — | — | US | disclosed |
| WO-2006091246-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2006-08-31 | — | — | WO | disclosed |
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | UNIVERSITY OF SOUTHERN CALIFORNIA | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142294-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, LIPG | HSD17B3 3319/4885ESR1 2936/4885ESR2 1009/4885 |
| US-20110275646-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, LIPG | HSD17B3 3319/4885ESR1 2936/4885ESR2 1009/4885 |
| US-20110034472-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated With Angiogenesis Function | VEGFA, TEK, MCL1 | HSD17B3 3370/4885ESR1 3152/4885ESR2 1232/4885 |
| US-20090093489-A1 | NOVEL COMPOUNDS FOR TREATMENT OF CANCER AND DISORDERS ASSOCIATED WITH ANGIOGENESIS FUNCTION | VEGFA, TEK, MCL1 | HSD17B3 3370/4885ESR1 3152/4885ESR2 1232/4885 |
| US-20100120781-A1 | Novel Compounds for Treatment of Cancer and Disorders Associated with Angiogenesis Function | VEGFA, TEK, MCL1 | HSD17B3 3370/4885ESR1 3152/4885ESR2 1232/4885 |
| US-20060235034-A1 | Novel compounds for treatment of cancer and disorders associated with angiogenesis function | VEGFA, TEK, MCL1 | HSD17B3 3370/4885ESR1 3152/4885ESR2 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.